Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q3 FY26 results · Oct–Dec 2025
Suven Life Sciences reported revenue from operations of ₹2.81 crore (up 74.5% from Q3 FY25) and net loss of ₹101.92 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.81 | 1.61 | +74.5% | 0.92 | +205.6% |
| Other income | 2.77 | 1.63 | +70.2% | 3.78 | −26.6% |
| Total income | 5.58 | 3.24 | +72.3% | 4.70 | +18.9% |
| Profit before tax | (101.92) | (39.12) | Loss widened | (77.31) | Loss widened |
| Net profit for the period | (101.92) | (39.12) | Loss widened | (77.31) | Loss widened |
| EPS, basic (₹) | (4.55) | (1.79) | Loss widened | (3.48) | Loss widened |
| Net margin (%) | -3628.8 | -2429.8 | -8410.6 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.81 | 1.61 | +74.5% | 0.92 | +205.6% |
| Other income | 2.77 | 1.57 | +76.3% | 3.78 | −26.8% |
| Total income | 5.57 | 3.18 | +75.3% | 4.70 | +18.7% |
| Profit before tax | (13.47) | (13.27) | Loss widened | (15.45) | Loss narrowed |
| Net profit for the period | (13.47) | (13.27) | Loss widened | (15.45) | Loss narrowed |
| EPS, basic (₹) | (0.60) | (0.61) | Loss narrowed | (0.70) | Loss narrowed |
| Net margin (%) | -479.6 | -824.4 | -1680.3 |
Consolidated
- Filed with BSE
- 29 Jan 2026, 15:02 IST
- Board meeting
- 29 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jan 2026, 15:02 IST
- Board meeting
- 29 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE